weight regain tirzepatide enhances loss with sustained treatment but discontinuation leads to weight People who stop taking weight-loss

Travel and injection site considerations Maintaining your tirzepatide schedule while traveling adds logistical challenges to injection site management

If you are breastfeeding or planning to become pregnant, discuss timing with your provider before switching

Lilly announced results from its Phase 3 TRIUMPH-4 trial of retatrutide, a first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, on Thursday

Some people simply respond better to a medication that works on a second hormone pathway

Periodic reassessment of goals, side effects, and metabolic markers is essential

This partly explains why the current trial showed lower average weight loss than previous studies, which had fewer male participants